Роль пентраксину-3 та нових неінвазивних методів у діагностиці неалкогольного стеатогепатиту
DOI:
https://doi.org/10.30978/MG-2018-3-124Ключові слова:
неалкогольна жирова хвороба печінки, неалкогольний стеатогепатит, пентраксин-3Анотація
Огляд присвячено проблемі діагностики однієї з найпоширеніших патологій сучасного світу — неалкогольної жирової хвороби печінки. Розглянуто нові неінвазивні методи діагностики неалкогольного стеатогепатиту. Узагальнено патогенетичні механізми впливу пентраксину-3 на розвиток неалкогольного стеатогепатиту. Наведено дані експериментальних і клінічних досліджень щодо значення пентраксину-3 у неінвазивній діагностиці неалкогольного стеатогепатиту.
Посилання
Babak OYa, Kolesnikova EV, Dubrov KYu. The nonalcoholic liver steatosis is a «chord» of metabolic disturbances (Russian). 2011;1;5.
Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance. Hepatol. 2010;51(2):373-375.
Azzurri A, Sow OY, Amedei A et al. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect. 2005;N 7 (1):1-8.
Boga S, Koksal AR. Plasma pentraxin 3 differentiates nonalcoholic steatohepatitis (NASH) from non-NASH. Metab Syndr Relat Disord. 2015;13(9):393-399.
doi: 10.1089/met.2015.0046. Epub. 2015 Sep 14.
Byrne C, Targher G. NAFLD: A multisystem disease. J Hepatol. 2015;62. P. S47–S64.
Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholicfatty liver disease. Qjm. 2010;103(2):71-83.
Ekstedt M et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatol. 2006;44(4):865-873.
Emsley J, White HE, O’Hara BP. Structure of pentameric human serum amyloid P component. Nature. 1994;367 (6461). P. 338-345. doi: 10.1038/367338a0.PMID8114934.
Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinicalfeatures and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis. 2001;21:17-26.
Farrell GC, Chitturi S, Lau GK, Asia-Pacific working party on nafld. Guidelines for the assessment and management of non-alcoholicfatty liver disease in the Asia–Pacific region: executive summary. J Gastroenterol Hepatol. 2007;22(6):775-777.
Fazzini F, Peri G, Doni A et al. PTX3 in small-vessel vasculitides:. an independent indicator of disease activity produced at sites of inflammation. Arthritis & Rheumatism. 2001;Vol. 44, N 12:2848.
Fornai F, Carrizzo A. The inflammatory protein Pentraxin 3 in cardiovascular disease. Immunity & Ageing. 2016;13:25. doi: 10.1186/s12979-016-0080-1.
Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337-366. doi: 10.1146/annurev.immunol.23.021704.115756.PMID15771574.
Gewurz H, Zhang XH, Lint TF. Structure and function of the pentraxins. Curr Opin Immunol. 1995;7:54-64.
Hamza RT, Elfaramawy AA, Mahmoud NH. Serum Pentraxin 3 fragment as a noninvasive marker of nonalcoholic fatty liver disease. Horm Res Paediatr. 2016;86(1):11-20. doi: 10.1159/000446566. Epub 2016 Jun 17.
Heiner W, Manns M. Fatty liver disease — it’s more than alcohol and obesity. Medscape Gastroenterol. 2003;5(2). P. 3.
Histological evaluation of nonalcoholic fatty liver disease and its correlation with different noninvasive scoring systems with special reference to fibrosis: A single center experience. Exp Hepatol. 2016;6. P. 291.
Iijima H, Moriyasu F, Tsuchiya K et al. Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis. Hepatol Res. 2007;37:722-730.
Introna M, Alles VV, Castellano M et al. Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood. 1996;87:1862-1872.
JunYu, Jiayun Shen. Obesity, insulin resistance, NASH and hepatocellular carcinoma. Seminars in Cancer Biology. 2013;Vol. 23, Iss. 6, Part B:483-491.
Latini R, Maggioni AP, Peri G et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004;110:2349.
Masato Yoneda, Takashi Uchiyama. Plasma Pentraxin 3 is a novel marker for nonalcoholic steatohepatitis (NASH). BMC Gastroenterol. 2008;Published online 2008 Nov 14.
McPherson S, Hardy T. Evidence of NAFLD progression from steatosis tofibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. J Hepatol. 2015;62:1148-1155.
Mishra P, Younossi ZM. Abdominal ultrasound for diagnosis ofnonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol. 2007;102:2716-2717.
Mofrad P, Contos MJ, Haque M et al. Clinical and histologic spectrumof nonalcoholic fatty liver disease associated with normal ALT values. Hepatol. 2003;37:1286-1292.
Muller B, Peri G, Doni A et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med. 2001;29(7):1404-1407.
Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatol. 2003;37(5):1202-1219.
Ozturk K, Kurt O. Pentraxin 3 is a predictor for fibrosis and arterial stiffness in patients with nonalcoholic fatty liver disease. Gastroenterology Research and Practice. 2016;2016. Article ID 1417962.
Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association The Diagnosis and Management of Non-Alcoholic Fatty Liver Disease. Hepatol. 2012;55, N 6:2009.
Ratziu V et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterol. 2005;128.7:1898-1906.
Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fattyliver. Am J Roentgenol. 2007;189. P. W320-323.
Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatol. 2010;52, N 5:1837.
Tözün N, Avsar E, Day CP. Pathogenesis of steatohepatitis. Non Alcoholic Fatty Liver Disease — EASL 2003 President’s Premeeting Syllabus. 2003:11-28.
Wong VW, Chu WC, Wong GL et al. Prevalence of non-alcoholic fattyliver disease and advanced fibrosis in Hong Kong Chinese: a populationstudy using proton-magnetic resonance spectroscopy andtransient elastography. Gut. 2012;61:409-415. Epub. 2011 Aug 16.
Wong VW, Vergniol J, Wong GL et al. Diagnosis of fibrosis andcirrhosis using liver stiffness measurement in nonalcoholic fattyliver disease. Hepatol. 2010;51:454-462.
Yilmaz Y. Is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?. Aliment Pharmacol Ther. 2012;36(9):815-823.
